Latest News & Features
Refine Search
Americas
Alnylam backed down after judge’s patent interpretation favoured Moderna | Case is part of a spate of infringement lawsuits aimed at both Moderna and Pfizer | Plaintiff may be allowed to refile in future. 3 October 2024
Americas
German pharma giant claims Granules India’s ANDA infringes five patents I Combination therapy Jentadueto among Boehringer’s top three products in 2023 3 October 2024
Europe
Janssen Biotech denied permission to appeal invalidation of ustekinumab patent I Samsung Bioepis convinced UK court to revoke patent in July. 1 October 2024
Unified Patent Court
Having been involved in more than 30 cases at the UPC, the Bardehle Pagenberg litigator tells Marisa Woutersen why success at the game-changing court is a team effort. 1 October 2024
Europe
A request by CRISPR scientists to withdraw their patents over allegations of mishandling by the EPO’s Boards of Appeals has thrust a ‘fundamentally unfair, uncertain system’ into sharp focus, finds Sarah Speight. 27 September 2024
Europe
Jennifer Godorn Wessman is leading efforts to protect the medtech company’s key assets. She sat down with LSIPR to discuss her team’s challenges, expanding into new markets, and why lawyers are salespeople too. 26 September 2024
Europe
WIPO’s Global Innovation Index reveals most innovative nations | Higher-value inventions attracting investors in a more difficult climate | Switzerland retains most innovative economy spot with India’s ‘exciting’ growth a highlight. 26 September 2024
Unified Patent Court
Cameron Marshall, partner at Carpmaels, offers a behind-the-scenes snapshot of working a UPC case with tight deadlines and an unusual result, finds Sarah Speight. 26 September 2024
Biotechnology
The shift towards preventative pharmaceuticals could open new, and highly valuable, markets but it must be strengthened by patent rights, says Sam Andrews, senior paralegal at Powell Gilbert. 24 September 2024
Americas
Biotech’s motion for preliminary injunction to prevent Eylea biosimilar rejected I Regeneron has filed multiple suits over rivals’ copies of aflibercept. 24 September 2024